- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03078062
Impact of Dexamethasone on the Duration of Sensory and Motor Block Following Spinal Anesthesia
Impact of Intravenous Dexamethasone on the Duration of Sensory and Motor Block Following a Bupivacaine-based Spinal Anesthesia
The purpose of this study is to assess the effect of a single-dose of intravenous dexamethasone 8 mg on the duration of sensory and motor blockade following spinal anesthesia with isobaric bupivacaine.
The hypothesis of the study is that intravenous dexamethasone will significantly prolong (by more than 20 minutes) the duration of spinal anesthesia.
Study Overview
Status
Intervention / Treatment
Detailed Description
Spinal anesthesia is commonly used for lower body surgery. The injection of local anesthetics in the lumbar intrathecal space allows the desensitization of the lower body by blocking sensory and motor nerve roots. In return, spinal anesthesia causes a sympathetic block which is associated with deleterious hemodynamic effects such as hypotension.
Using intravenous or intrathecal adjuvants to local anesthetics may prolong the duration of sensory and motor blockade following spinal anesthesia. Various intrathecal additives have been studied such as opioids, adrenalin, clonidine, dexmedetomidine, midazolam, ketamine, magnesium, ketorolac and neostigmine. Most of them failed to prolong the duration of spinal anesthesia and side-effects have restricted their use.
Dexamethasone is a potent corticosteroid with a half-life of 36 to 72 hours and an onset of action of 1 to 2 hours. The safety of single doses of intravenous dexamethasone is well documented. Dexamethasone is widely used in anesthesia to prevent nausea and vomiting and treat post-extubation sore throat and postoperative shivering. It is also increasingly used in orthopaedic surgery to reduce opioid needs without increasing the risks of infection, wound dehiscence and osteonecrosis. The use of dexamethasone in the perioperative period reduces postoperative edema allowing early mobilization and improved functional recovery.
Recent studies have demonstrated that both perineural and intrathecal administration of dexamethasone can prolong the duration of peripheral and spinal anesthesia. However, dexamethasone has not been approved by health authorities for these indications and thus, the safety of this practice remains controversial. A recent study has compared peripheral to intravenous administration of dexamethasone for interscalene blocks. This study demonstrated the equivalency of these regimens in increasing the analgesic duration of a single-shot interscalene block.
The impact of intravenous dexamethasone on the duration of spinal anesthesia remains unknown. This study will investigate the effect of a single-dose of dexamethasone 8 mg on the duration of the sensory and motor block following spinal anesthesia.
Sixty patients scheduled for lower body surgery under spinal anesthesia will be considered for this study.
After placement of standard non-invasive monitoring, spinal anesthesia will be performed in the sitting position using a 25 gauge (GA) pencil point needle (Whitacre, Pencan). After aspiration of cerebrospinal fluid (CSF), a dose of isobaric 0.5% bupivacaine 12 mg will be injected. The aspiration of CSF will be repeated at the end of the injection. While performing spinal anesthesia, an intravenous infusion of dexamethasone 8 mg or placebo will be initiated according to randomization.
Subsequently, the patient will be placed in supine position. Sensory block will be measured by loss of sensation to pinprick at 5, 10, 20 and 30 minutes following spinal anesthesia and then every 15 minutes until confirmation of regression by two dermatomes. Loss of sensation will be assessed every 30 minutes thereafter. Motor block will be assessed using the Bromage scale at the same frequency until full recovery.
Sedation will be allowed during the performance of the spinal anesthesia technique and surgery. In case of unsatisfactory quality of spinal anesthesia, general anesthesia will be performed.
At the end of surgery, patients will be transferred to the recovery room. Multimodal analgesia including celecoxib and acetaminophen will be administered. Pain will be assessed using a verbal numeric pain scale (VNPS) of 0 to 10, where 0 means "No pain" and 10 means "Worst pain imaginable". Intravenous hydromorphone will be administered when VNPS is superior to 3. Postoperative nausea and vomiting will be managed with intravenous ondansetron, dimenhydrinate and haloperidol.
Opioid intake, presence of side-effects and quality of sleep will be assessed during the first 24 hours following surgery.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 4M1
- Centre Hospitalier de l'Universite de Montreal (CHUM)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients undergoing lower body surgery under spinal anesthesia
- American Society of Anesthesiologists' physical status of 1 to 3
Exclusion Criteria:
- Contraindication to spinal anesthesia (coagulopathy, local infection at the site of injection)
- Pre-existing neuropathy or nerve block that could compromise study assessments
- Preoperative use of systemic corticosteroids
- Allergy or hypersensitivity to local anesthetics, dexamethasone or other drugs used in this study
- Patient refusal or inability to consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Dexamethasone
During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated.
The study drug will be administered over 5 -10 minutes diluted in a 500 ml bag of Normal Saline for a total volume of 502 ml.
The study drug will be prepared by an independent assistant.
|
Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia
Other Names:
|
Placebo Comparator: Normal Saline
During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of 502 ml of Normal Saline will be initiated.
The infusion will be administered over 5 -10 minutes.
The study drug will be prepared by an independent assistant.
|
Administration of a single-dose of Normal saline during spinal anesthesia
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Regression of sensory block by 2 dermatomes
Time Frame: At regression of spinal anesthesia by 2 dermatomes, approximately 2 hours after surgery
|
Loss of pinprick sensation by Von Frey filaments from the injection of bupivacaine for spinal anesthesia until regression of the sensory block by two dermatomes from the peak sensory level
|
At regression of spinal anesthesia by 2 dermatomes, approximately 2 hours after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of motor block
Time Frame: At 5,10, 20 and 30 minutes following spinal anesthesia, then every 15 minutes until regression of 2 dermatomes and every 30 minutes thereafter until complete recovery, approximately 4 hours after surgery
|
Using the Bromage scale from the time of injection of bupivacaine for spinal anesthesia until complete recovery of motor block
|
At 5,10, 20 and 30 minutes following spinal anesthesia, then every 15 minutes until regression of 2 dermatomes and every 30 minutes thereafter until complete recovery, approximately 4 hours after surgery
|
Onset of sensory block
Time Frame: Up to 30 minutes following spinal anesthesia
|
Time from injection of bupivacaine for spinal anesthesia to reduction of sensitivity using loss of pinprick sensation
|
Up to 30 minutes following spinal anesthesia
|
Onset of motor block
Time Frame: Up to 30 minutes following spinal anesthesia
|
Time from injection of bupivacaine for spinal anesthesia to reduction of lower limbs movement using the Bromage scale
|
Up to 30 minutes following spinal anesthesia
|
Quality of motor block
Time Frame: Up to 30 minutes following spinal anesthesia
|
Maximal Bromage score
|
Up to 30 minutes following spinal anesthesia
|
Surgeon's satisfaction towards spinal anesthesia
Time Frame: At the end of surgery, on the day of randomization
|
Unsatisfied or satisfied
|
At the end of surgery, on the day of randomization
|
Time to first analgesic request
Time Frame: From the end of surgery up to approximately six hours after surgery, on the day of randomization
|
First request by the patient for an analgesic or pain superior to 3 on a scale from 0 to 10; where 0 means "no pain at all" and 10 means "worst pain imaginable"
|
From the end of surgery up to approximately six hours after surgery, on the day of randomization
|
Opioid consumption
Time Frame: At recovery room discharge, approximately one hour after the end of surgery on the day of randomization and 24 hours following surgery
|
Total dose of opioids
|
At recovery room discharge, approximately one hour after the end of surgery on the day of randomization and 24 hours following surgery
|
Incidence of hypotension
Time Frame: From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Systolic blood pressure lower than 90 mm Hg
|
From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Incidence of bradycardia
Time Frame: From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Heart rate slower than 50 beats per minute
|
From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Incidence of nausea
Time Frame: From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Any episode of nausea reported by the patient or nursing team
|
From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Incidence of vomiting
Time Frame: From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Any episode of retching or vomiting reported by the patient or nursing team
|
From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Incidence of urinary retention
Time Frame: From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Any episode of urinary retention reported by the patient or nursing team
|
From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Incidence of shivering
Time Frame: From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Any episode of shivering reported by the patient or nursing team
|
From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Incidence of headache
Time Frame: From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Any episode of headache reported by the patient or nursing team
|
From injection of bupivacaine for spinal anesthesia to 24 hours after surgery
|
Quality of sleep
Time Frame: At 24 hours after surgery
|
Described by the patient as good or bad
|
At 24 hours after surgery
|
Duration of sensory block
Time Frame: At 5,10, 20 and 30 minutes following spinal anesthesia, then every 15 minutes until regression by 2 dermatomes and every 30 minutes thereafter until complete recovery, approximately 4 hours after surgery
|
Loss of pinprick sensation by Von Frey filaments from the injection of bupivacaine for spinal anesthesia until complete recovery
|
At 5,10, 20 and 30 minutes following spinal anesthesia, then every 15 minutes until regression by 2 dermatomes and every 30 minutes thereafter until complete recovery, approximately 4 hours after surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stephan R Williams, MD, PhD, Centre Hospitalier de l'Universite de Montreal (CHUM)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16.374
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Anesthesia
-
Samsung Medical CenterCompletedSpinal Anesthesia | Success or Failure of Spinal AnesthesiaKorea, Republic of
-
University of Alabama at BirminghamCompleted
-
Universidade do Vale do SapucaiCompletedAnesthesia, Epidural | Anesthesia, Spinal | AntisepsisBrazil
-
San Salvatore Hospital of L'AquilaRecruitingAnesthesia, Local | Anesthesia; Functional | Spinal CordItaly
-
Antalya Training and Research HospitalCompletedAnesthesia, General | Anesthesia, Spinal | Umbilical CordTurkey
-
Oregon Health and Science UniversityB. Braun Medical Inc.SuspendedAnesthesia, SpinalUnited States
-
KK Women's and Children's HospitalNational University of SingaporeActive, not recruitingSpinal Anesthesia
-
Hopital MontfortWithdrawn
-
Seoul National University Bundang HospitalCompleted
-
Cairo UniversityCompleted
Clinical Trials on Dexamethasone
-
Ottawa Hospital Research InstituteCompletedPain Syndrome | Early-stage Breast CancerCanada
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting
-
Centre hospitalier de l'Université de Montréal...CompletedPrevention of Hypersensitivity Reactions to PaclitaxelCanada
-
Vanderbilt University Medical CenterTerminatedAsthma | CroupUnited States
-
Dr. Stephen ChoiThe Physicians' Services Incorporated FoundationCompletedShoulder Surgery | Nerve BlockCanada
-
Universidade Federal de PernambucoCompletedDiabetic Macular EdemaBrazil
-
Shanghai Jiao Tong University Affiliated Sixth...CompletedAnalgesia | Time | Brachial Plexus Block | Shoulder Surgery | Dexamethasone | Intravenous Drug UsageChina
-
Poznan University of Medical SciencesRecruitingWrist Injuries | Hand Injuries | Hand Injuries and Disorders | Hand Disease | Wrist DiseasePoland
-
University of California, San FranciscoCompletedOral Lichen Planus | Pemphigus Vulgaris | Mucous Membrane Pemphigoid | Chronic Graft-versus-host-diseaseUnited States
-
University of BelgradeCompleted